ISIS 11061
Latest Information Update: 01 May 2003
At a glance
- Originator Isis Pharmaceuticals
- Class Antineoplastics; Antisense oligonucleotides
- Mechanism of Action Phosphotransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Vascular restenosis
Most Recent Events
- 03 Mar 2000 New profile
- 03 Mar 2000 Preclinical development for Vascular restenosis in USA (Unknown route)